Hydrogels are among the most widely studied biomaterials in modern drug delivery research. Their high hydrophilicity, ...
Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...
Complement activation in immunological neurological disorders: mechanisms and therapeutic strategies
Recent advances in the understanding of immune-mediated neurological disorders have led to a paradigm shift toward pathophysiology-directed therapies. Central to this progress is a deeper appreciation ...
Light and heavy chain deposition disease (LHCDD) is a clonal plasma cell or monoclonal B-cell dyscrasia characterized by deposition of monoclonal immunoglobulin light and heavy chains. LHCDD mainly ...
The last time I spoke about Omeros Corporation (OMER) it was in a Seeking Alpha article entitled "Omeros: FDA Appeal On Nasoplimab And Several 2023 Catalysts On Deck." Since then, it has faced several ...
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. The interactions of nanoparticles (NPs) with macrophages after intravenous injection ...
The triple therapy showed a 50% overall response rate and 22-month median overall survival in MSS BRAF V600E-mutant mCRC patients. Targeting MAPK signaling with encorafenib and cetuximab may prime ...
Please provide your email address to receive an email when new articles are posted on . SAR446597 is designed to inhibit C1s and factor Bb in the complement pathway. Fast track designation expedites ...
Sickle cell disease can lead to a severe complication known as acute chest syndrome (ACS), but the underlying mechanisms are not well understood. A new study by Mass General Brigham investigators ...
SEOUL, South Korea--(BUSINESS WIRE)--ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared ...
Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback